<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary cutaneous T cell lymphomas, rare subtypes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary cutaneous T cell lymphomas, rare subtypes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary cutaneous T cell lymphomas, rare subtypes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rein Willemze, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1060059838"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term "primary cutaneous T cell lymphoma" (CTCL) refers to T cell lymphomas that present primarily in the skin without evidence of extracutaneous disease at the time of diagnosis. The group of classical CTCLs (mycosis fungoides, variants of mycosis fungoides, and Sézary syndrome) and the group of primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders (anaplastic large cell lymphoma and lymphomatoid papulosis) encompass the most common forms of CTCLs, accounting for approximately 90 percent of CTCLs in the Western world [<a href="#rid1">1</a>]. However, different distributions have been observed in other parts of the world [<a href="#rid2">2,3</a>].</p><p>Other types of CTCLs recognized in the 2018 update of the World Health Organization (WHO)-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas [<a href="#rid1">1</a>] and in the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissue [<a href="#rid4">4</a>] include uncommon entities, such as subcutaneous panniculitis-like T cell lymphoma; extranodal natural killer/T cell lymphoma, nasal type; primary cutaneous peripheral T cell lymphoma (PTCL), not otherwise specified; and rare subtypes of PTCL [<a href="#rid1">1,4</a>].</p><p>This topic will focus on rare subtypes of primary cutaneous PTCL, which include:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary cutaneous gamma-delta T cell lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Primary cutaneous aggressive epidermotropic CD8<sup>+</sup> cytotoxic T cell lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Primary cutaneous acral CD8<sup>+</sup> T cell lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder</p><p></p><p>Mycosis fungoides, Sézary syndrome, primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders, and other uncommon types of CTCL are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16193.html" rel="external">"Clinical presentation, pathologic features, and diagnosis of Sézary syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/99486.html" rel="external">"Primary cutaneous anaplastic large cell lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15725.html" rel="external">"Lymphomatoid papulosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4744.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4712.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type"</a>.)</p><p></p><p class="headingAnchor" id="H3215520080"><span class="h1">PRIMARY CUTANEOUS GAMMA-DELTA T CELL LYMPHOMA</span><span class="headingEndMark"> — </span>Primary cutaneous gamma-delta T cell lymphoma (PCGD-TCL) is a rare lymphoma composed of a clonal proliferation of mature, activated gamma-delta T cells with a cytotoxic phenotype and characterized by rapid progression and poor prognosis [<a href="#rid1">1,4</a>]. This group includes cases previously known as subcutaneous panniculitis-like T cell lymphoma (SPTCL) with a gamma-delta phenotype.</p><p class="headingAnchor" id="H977111405"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>PCGD-TCL is rare, representing less than 1 percent of all cutaneous T cell lymphomas (CTCLs) and with a cumulative incidence of 0.4 per 10 million individuals [<a href="#rid1">1,5</a>]. Most patients are adults, with a median age of approximately 60 years (range 25 to 91) [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H511037125"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Studies suggest a relationship between clinicopathologic presentation and cell of origin [<a href="#rid7">7</a>]. Superficial epitheliotropic lymphomas are derived from V-delta-1 cells, the predominant gamma-delta T cell in the epidermis and dermis, while panniculitic cases arise from V-delta-2 cells, the predominant gamma-delta T cell in the fat. V-delta-2 lymphomas are associated with inflammatory gene signatures that may contribute to the development of a hemophagocytic syndrome [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2652089255"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>PCGD-TCL usually presents with disseminated, rapidly progressing plaques and/or ulceronecrotic nodules or tumors, preferentially located on the extremities  (<a class="graphic graphic_picture graphicRef109196" href="/z/d/graphic/109196.html" rel="external">picture 1</a>) [<a href="#rid8">8,9</a>]. Mucosal and other extranodal sites are frequently involved, but involvement of lymph nodes, spleen, or bone marrow is uncommon. PCGD-TCL may be associated with a hemophagocytic syndrome, particularly in patients with panniculitis-like tumors [<a href="#rid8">8,9</a>]. B symptoms, including fever, night sweats, and weight loss, are seen in most patients. (See  <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p class="headingAnchor" id="H2462217364"><span class="h2">Pathology</span></p><p class="headingAnchor" id="H3552705443"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>In contrast with SPTCL, the neoplastic infiltrates of PCGD-TCL are not confined to the subcutaneous tissue but generally involve the epidermis and/or dermis as well [<a href="#rid8">8-10</a>]. Epidermal infiltration may occur as mild epidermotropism to marked pagetoid reticulosis-like infiltrates, which may be associated with intraepidermal vesiculation and necrosis. Angiocentricity, angiodestruction, and tissue necrosis are common. The neoplastic cells are generally medium to large in size with coarsely clumped chromatin  (<a class="graphic graphic_picture graphicRef109197" href="/z/d/graphic/109197.html" rel="external">picture 2</a>).</p><p class="headingAnchor" id="H4002759965"><span class="h3">Immunophenotype</span><span class="headingEndMark"> — </span>The neoplastic cells of PCGD-TCL characteristically have a T cell receptor (TCR)-gamma/delta<sup>+</sup>, beta-F1<sup>-</sup>, CD3<sup>+</sup>, CD2<sup>+</sup>, CD5<sup>-</sup>, CD4<sup>-</sup>, CD8<sup>-</sup>, CD56<sup>+</sup> phenotype with strong expression of cytotoxic proteins  (<a class="graphic graphic_picture graphicRef109198" href="/z/d/graphic/109198.html" rel="external">picture 3</a>) [<a href="#rid8">8,9,11,12</a>]. CD30 may be expressed by a subset of patients [<a href="#rid13">13</a>]. Coexpression of TCR-gamma/delta and beta-F1 has been reported in some cases [<a href="#rid14">14</a>]. Epstein-Barr virus is negative.</p><p class="headingAnchor" id="H2076779603"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>Most cases of PCGD-TCL show clonally rearranged TCR-gamma and TCR-delta genes. No other genetic features have been reported.</p><p class="headingAnchor" id="H3359917847"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of PCGD-TCL requires the integration of clinical, histologic, phenotypic, and molecular genetic data. Deep punch biopsies (≥4 mm) or incisional biopsies can be performed for routine histopathology, immunophenotyping, and molecular analysis. A new commercially available TCR-delta antibody has been extremely helpful in differentiating between PCGD-TCL and other aggressive primary CTCLs with a cytotoxic T cell phenotype [<a href="#rid15">15</a>]. However, it should be noted that TCR-gamma/delta expression is found not only in PCGD-TCL but also in other types of CTCLs, including rare cases of otherwise classical mycosis fungoides (MF) and lymphomatoid papulosis type D [<a href="#rid14">14,16,17</a>].</p><p class="headingAnchor" id="H615099160"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of PCGD-TCL includes SPTCL and MF.</p><p class="headingAnchor" id="H2308806457"><span class="h3">Subcutaneous panniculitis-like T cell lymphoma</span><span class="headingEndMark"> — </span>Both PCGD-TCL and SPTCL may present on histopathologic examination as nodular lesions with panniculitis-like features with rimming of fat cells  (<a class="graphic graphic_picture graphicRef118352 graphicRef118353" href="/z/d/graphic/118352.html" rel="external">picture 4A-B</a>). In contrast to SPTCL, PCGD-TCL commonly involves not only the subcutis but also the dermis and/or epidermis, either in the same biopsy or in different biopsies of lesional skin, and may show ulceration.</p><p>While SPTCL has an alpha-beta T cell phenotype, PCGD-TCL has a gamma-delta T cell phenotype, is generally negative for both CD4 and CD8, and commonly expresses CD56  (<a class="graphic graphic_table graphicRef109199" href="/z/d/graphic/109199.html" rel="external">table 1</a>). The differentiation of these two entities is important, since PCGD-TCL with panniculitis-like features generally has a poor prognosis and requires systemic combination chemotherapy [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/z/d/html/4744.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma"</a>.)</p><p class="headingAnchor" id="H1823462876"><span class="h3">Mycosis fungoides</span><span class="headingEndMark"> — </span>The histopathologic differentiation of PCGD-TCL from tumor-stage MF and, uncommonly, plaque-stage MF may be difficult. Clinicopathologic correlation is essential. While the neoplastic T cells in MF have TCR-gamma/delta<sup>-</sup>, beta-F1<sup>+</sup>, CD4<sup>+</sup>, or, less commonly, a CD8<sup>+</sup> T cell phenotype, the T cells in PCGD-TCL have a TCR-gamma/delta<sup>+</sup>, beta-F1<sup>-</sup>, CD4<sup>-</sup>, CD8<sup>-</sup> T cell phenotype. However, rare cases of otherwise classical MF expressing TCR-gamma have been reported [<a href="#rid14">14,16</a>]. Documentation of previous or concurrent presence of patch or plaque-like lesions strongly suggests a diagnosis of MF. (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p class="headingAnchor" id="H2930919974"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Because of its rarity, there are no randomized trials addressing the treatment of PCGD-TCL. These patients should be treated with combination chemotherapy using the regimens suggested for peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Pretreatment evaluation, initial treatment, and treatment of PTCL, NOS are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">"Initial treatment of peripheral T cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p>PCGD-TCL usually has an aggressive clinical course, is resistant to multiagent chemotherapy, and has a poor prognosis, with a median survival of approximately 15 months [<a href="#rid8">8,9</a>]. Patients with subcutaneous fat involvement tend to have a poorer prognosis than patients with epidermal or dermal disease only [<a href="#rid9">9,10</a>]. Rare cases of PCGD-TCL following a more indolent clinical course have been reported [<a href="#rid6">6,18,19</a>].</p><p class="headingAnchor" id="H3966910172"><span class="h1">PRIMARY CUTANEOUS CD8+ AGGRESSIVE EPIDERMOTROPIC CYTOTOXIC T CELL LYMPHOMA</span><span class="headingEndMark"> — </span>Primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T cell lymphoma (AECTCL) is a rare cutaneous lymphoma characterized by a proliferation of epidermotropic CD8<sup>+</sup> cytotoxic T cells, an aggressive clinical behavior, and poor prognosis [<a href="#rid20">20</a>]. CD8<sup>+</sup> AECTCL is included as a provisional entity in the 2018 update of the World Health Organization (WHO)-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas and in the 2016 revision of the WHO classification of hematopoietic neoplasms [<a href="#rid1">1,4</a>].</p><p class="headingAnchor" id="H286944658"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>CD8<sup>+</sup> AECTCL is rare, representing less than 1 percent of all cutaneous T cell lymphomas (CTCL) [<a href="#rid1">1</a>]. Most patients are adults. </p><p class="headingAnchor" id="H2670051392"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Patients with CD8<sup>+</sup> AECTCL present with localized or disseminated eruptive papules, nodules, and tumors showing central ulceration and necrosis  (<a class="graphic graphic_picture graphicRef109201" href="/z/d/graphic/109201.html" rel="external">picture 5</a>) or with superficial, hyperkeratotic patches and plaques [<a href="#rid20">20-22</a>]. CD8<sup>+</sup> AECTCL progresses rapidly over weeks to months and shows a propensity to disseminate to visceral sites such as the lung, testis, central nervous system, and oral mucosa, but lymph nodes are often spared [<a href="#rid20">20,22</a>]. Some patients may have a prodrome of chronic patches prior to the development of aggressive ulcerative lesions [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H2042083201"><span class="h2">Pathology</span></p><p class="headingAnchor" id="H340985578"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>The histopathologic appearance of CD8<sup>+</sup> AECTCL is variable, ranging from a lichenoid pattern with marked, pagetoid epidermotropism and subepidermal edema in early patch-like lesions to diffuse dermal infiltrates in nodular and tumor-like lesions  (<a class="graphic graphic_picture graphicRef109202" href="/z/d/graphic/109202.html" rel="external">picture 6</a>). Epidermal necrosis and ulceration as well as invasion and destruction of adnexal skin structures are commonly found [<a href="#rid20">20-22,24</a>]. Angiocentricity and angioinvasion may be present. Tumor cells are small-medium or medium-large with pleomorphic or blastic nuclei.</p><p class="headingAnchor" id="H459311579"><span class="h3">Immunophenotype</span><span class="headingEndMark"> — </span>The neoplastic T cells of CD8<sup>+</sup> AECTCL have a beta-F1<sup>+</sup>, CD3<sup>+</sup>, CD8<sup>+</sup>, granzyme B<sup>+</sup>, perforin<sup>+</sup>, TIA-1<sup>+</sup>, CD45RA<sup>+/-</sup>, CD45RO<sup>-</sup>, CD2<sup>-/+</sup>, CD4<sup>-</sup>, CD5<sup>-</sup>, CD7<sup>+/-</sup> phenotype  (<a class="graphic graphic_picture graphicRef109207" href="/z/d/graphic/109207.html" rel="external">picture 7</a>) [<a href="#rid20">20-22</a>]. CD30 is rarely expressed [<a href="#rid22">22,25</a>]. Epstein-Barr virus is negative [<a href="#rid22">22,26</a>].</p><p class="headingAnchor" id="H3963980722"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>The neoplastic T cells of CD8<sup>+</sup> AECTCL show clonal T cell receptor gene rearrangements. Overactivation of Janus kinase 2 (JAK2) signaling is common, which makes AECTCL susceptible to JAK2 inhibitors [<a href="#rid27">27,28</a>].</p><p class="headingAnchor" id="H304736455"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of CD8<sup>+</sup> AECTCL is based upon the combination of the clinical, histopathologic, and immunophenotypic findings described above. Deep punch biopsies (≥4 mm) or incisional biopsies can be performed for routine histopathology, immunophenotyping, and molecular analysis. Since several types of primary CTCLs express a CD8<sup>+</sup> cytotoxic T cell phenotype  (<a class="graphic graphic_table graphicRef109206" href="/z/d/graphic/109206.html" rel="external">table 2</a>), a careful clinicopathologic correlation is key to the correct diagnosis [<a href="#rid25">25,29</a>].</p><p class="headingAnchor" id="H3129258417"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of CD8<sup>+</sup> AECTCL includes several subtypes of CTCL that show infiltration of CD8<sup>+</sup> neoplastic T cells  (<a class="graphic graphic_table graphicRef109206" href="/z/d/graphic/109206.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2956283695"><span class="h3">Lymphomatoid papulosis</span><span class="headingEndMark"> — </span>Lymphomatoid papulosis (LyP) type D is a newly described histologic subtype of LyP that shows the same histologic and immunophenotypic characteristics as CD8<sup>+</sup> AECTCL [<a href="#rid30">30</a>]. However, in contrast with CD8<sup>+</sup> AECTCL, LyP type D has a clinical indolent behavior characterized by the recurrence of self-healing papulonecrotic lesions limited to the skin, without involvement of extracutaneous sites. (See  <a class="medical medical_review" href="/z/d/html/15725.html" rel="external">"Lymphomatoid papulosis"</a>.)</p><p class="headingAnchor" id="H227044828"><span class="h3">Primary cutaneous anaplastic large cell lymphoma</span><span class="headingEndMark"> — </span>Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) usually shows a CD4<sup>+</sup> CD30<sup>+</sup> T cell phenotype, but in rare instances it may express CD8 [<a href="#rid31">31</a>]. In contrast with CD8<sup>+</sup> AECTCL, which in most cases presents with multiple disseminated lesions, PC-ALCL usually presents with a solitary or a few clustered skin lesions. Rare cases of CTCL showing coexpression of CD8 and CD30 most likely belong to the spectrum of primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders, although CD8<sup>+</sup> AECTCL may occasionally also express CD30 [<a href="#rid22">22,25</a>]. (See  <a class="medical medical_review" href="/z/d/html/99486.html" rel="external">"Primary cutaneous anaplastic large cell lymphoma"</a>.)</p><p class="headingAnchor" id="H3313974397"><span class="h3">Mycosis fungoides</span><span class="headingEndMark"> — </span>Early lesions of CD8<sup>+</sup> AECTCL should be differentiated from patch- or plaque-stage mycosis fungoides (MF). Although in most cases MF has a CD4<sup>+</sup>, CD8<sup>-</sup> T cell phenotype, approximately 15 percent of cases of early-patch/plaque-stage MF show a CD4<sup>-</sup>, CD8<sup>+</sup> T cell phenotype with strong expression of cytotoxic proteins [<a href="#rid32">32</a>]. Differentiating CD8<sup>+</sup> AECTCL from rare cases of CD8<sup>+</sup> tumor-stage MF, which may also present with ulcerating tumors, is much more difficult. Clinical and histopathologic documentation of previous or concurrent patch or plaque lesions is essential for a correct diagnosis. Strong expression of CD30 in such cases argues against a diagnosis of CD8<sup>+</sup> AECTCL [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p class="headingAnchor" id="H2206975216"><span class="h3">Pagetoid reticulosis</span><span class="headingEndMark"> — </span>On histology, early lesions of CD8<sup>+</sup> AECTCL that show marked pagetoid epidermotropism of neoplastic CD8<sup>+</sup> cytotoxic T cells may closely resemble pagetoid reticulosis, a rare variant of MF characterized by intraepidermal proliferation of neoplastic T cells. Pagetoid reticulosis typically presents with a solitary, slowly progressive, psoriasiform or hyperkeratotic patch or plaque or with a solitary, hyperkeratotic, wart-like lesion at the distal extremities. Unlike CD8<sup>+</sup> AECTCL, the neoplastic T cells in pagetoid reticulosis may have either a CD4<sup>+</sup>, CD8<sup>-</sup> or a CD4<sup>-</sup>, CD8<sup>+</sup> T cell phenotype and often express CD30 [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H339129503"><span class="h3">Subcutaneous panniculitis-like T cell lymphoma</span><span class="headingEndMark"> — </span>Subcutaneous panniculitis-like T cell lymphoma (SPTCL) presents with nodular skin lesions most often located on the legs. The neoplastic T cells express CD8 and the cytotoxic proteins TIA-1, granzyme B, and perforin. However, in contrast with CD8<sup>+</sup> AECTCL, the infiltrates of SPTCL are restricted to the subcutis, and epidermotropism is absent [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/4744.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma"</a>.) </p><p class="headingAnchor" id="H3568978086"><span class="h3">Primary cutaneous acral CD8+ T cell lymphoma</span><span class="headingEndMark"> — </span>The main differences between primary cutaneous acral CD8<sup>+</sup> T cell lymphoma and tumor-like lesions of CD8<sup>+</sup> AECTCL include the presence of a solitary lesion at acral sites (particularly the ears), an indolent clinical behavior, lack of epidermotropism, negative staining for granzyme B, and low proliferation rate. (See <a class="local">'Primary cutaneous acral CD8+ T cell lymphoma'</a> below.)</p><p class="headingAnchor" id="H652721910"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Because of its rarity, there are no randomized trials addressing the treatment of CD8<sup>+</sup> AECTCL. Patients are usually treated with combination chemotherapy, using the regimens for peripheral T cell lymphoma (PTCL), not otherwise specified. Pretreatment evaluation, initial treatment, and treatment of relapsed or refractory PTCL are presented elsewhere. Complete and durable remissions after allogeneic stem cell transplantation have been reported in selected cases [<a href="#rid23">23,35,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">"Initial treatment of peripheral T cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p>The clinical course of CD8<sup>+</sup> AECTCL is aggressive, and the response to chemotherapy is often disappointing. The reported median survival is less than two years [<a href="#rid20">20-23</a>]. </p><p class="headingAnchor" id="H646240243"><span class="h1">PRIMARY CUTANEOUS ACRAL CD8+ T CELL LYMPHOMA</span><span class="headingEndMark"> — </span>Primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is a newly described entity histologically characterized by a diffuse infiltrate of medium-sized CD8<sup>+</sup> cytotoxic T cells suggesting a high-grade malignant lymphoma and an indolent clinical behavior [<a href="#rid37">37</a>]. This condition, initially designated "indolent CD8-positive lymphoid proliferation of the ear," has been included as a provisional entity in the 2018 update of the World Health Organization (WHO)-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas and in the 2016 revision of the WHO classification [<a href="#rid1">1,4</a>].</p><p class="headingAnchor" id="H4206581917"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is rare. It has been reported only in adults and shows a male predominance.</p><p class="headingAnchor" id="H3773574672"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Patients with primary cutaneous acral CD8<sup>+</sup> T cell lymphoma typically present with a solitary, slowly progressive papule or nodule, most commonly located on the ear  (<a class="graphic graphic_picture graphicRef109234" href="/z/d/graphic/109234.html" rel="external">picture 8</a>). Similar lesions may occur at other acral sites including the nose and the foot [<a href="#rid37">37-41</a>]. In rare cases, both ears or feet may be affected [<a href="#rid37">37,40-43</a>]. One report describes a patient with recurrent and multifocal lesions on several acral sites [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H1390843739"><span class="h2">Pathology</span></p><p class="headingAnchor" id="H1613636157"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>The lesions of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma show a diffuse proliferation of monomorphous, medium-sized blast cells throughout the dermis and subcutis, separated from the epidermis by a clear grenz zone  (<a class="graphic graphic_picture graphicRef109235" href="/z/d/graphic/109235.html" rel="external">picture 9</a>) [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H3697945490"><span class="h3">Immunophenotype</span><span class="headingEndMark"> — </span>The tumor cells have a CD3<sup>+</sup>, CD4<sup>-</sup>, CD8<sup>+</sup>, TIA-1<sup>+</sup>, granzyme B<sup>-</sup>, CD30<sup>-</sup> T cell phenotype  (<a class="graphic graphic_picture graphicRef109235" href="/z/d/graphic/109235.html" rel="external">picture 9</a>) [<a href="#rid37">37,40</a>]. CD68 often shows a positive Golgi dot-like staining [<a href="#rid43">43</a>]. Loss of pan-T cell antigens (CD2, CD5, CD7) may occur. In almost all cases, the proliferation rate is very low (&lt;10 percent). Epstein-Barr virus is negative.</p><p class="headingAnchor" id="H1567064775"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>The neoplastic T cells of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma show clonal T cell receptor gene rearrangements. Specific genetic abnormalities have not been described.</p><p class="headingAnchor" id="H2411723022"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is based upon the finding of a solitary, slowly growing papule or nodule on the ear or other acral site that demonstrates on histopathologic examination a diffuse proliferation of monomorphous CD8<sup>+</sup> medium-sized blast cells. An excisional biopsy can be performed for lesions that are small (&lt;2 cm) and well demarcated. For larger lesions, deep punch biopsies (≥4 mm) or incisional biopsies are appropriate for diagnosis. In contrast with aggressive CD8<sup>+</sup> primary cutaneous T cell lymphoma, the proliferation rate is typically low.</p><p class="headingAnchor" id="H2834565175"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma includes benign and malignant lesions that may also present with a solitary papule or nodule on the ears, nose, or other acral sites. These include, among others, primary cutaneous follicle center lymphoma, folliculotropic mycosis fungoides, and, in particular, cutaneous B cell pseudolymphomas  (<a class="graphic graphic_picture graphicRef103721" href="/z/d/graphic/103721.html" rel="external">picture 10</a>). However, the demonstration of a diffuse proliferation of CD8<sup>+</sup> T cells on histopathologic examination suggests the correct diagnosis. (See  <a class="medical medical_review" href="/z/d/html/102748.html" rel="external">"Cutaneous B cell pseudolymphoma"</a>.)</p><p class="headingAnchor" id="H2580171248"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Surgical excision or radiotherapy usually results in complete remission. Relapses may occur and are often localized at the same acral site [<a href="#rid40">40</a>]. However, dissemination to extracutaneous sites is exceptional [<a href="#rid44">44</a>]. The recognition that these lesions have an indolent clinical behavior, despite an aggressive histology, is important to prevent unnecessarily aggressive treatment. The prognosis of primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is excellent,<strong> </strong>and in typical cases, staging is <strong>not</strong> recommended [<a href="#rid37">37,40</a>]. </p><p class="headingAnchor" id="H622037723"><span class="h1">PRIMARY CUTANEOUS CD4+ SMALL/MEDIUM T CELL LYMPHOPROLIFERATIVE DISORDER</span><span class="headingEndMark"> — </span>In the 2018 update of the World Health Organization (WHO)-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas and in the 2016 revision of the WHO classification, primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoma was included as a provisional type of primary cutaneous T cell lymphoma (CTCL), defined by a predominance of small- to medium-sized CD4<sup>+</sup> pleomorphic T cells without prior or concurrent patches and plaques typical of mycosis fungoides (MF) [<a href="#rid1">1,4</a>]. It has been recognized that cases presenting with a solitary plaque or tumor have the same clinicopathologic and immunophenotypic features and the same benign clinical course as cutaneous T cell pseudolymphomas with a nodular growth pattern [<a href="#rid45">45-47</a>] (see  <a class="medical medical_review" href="/z/d/html/15723.html" rel="external">"Cutaneous T cell pseudolymphomas", section on 'Idiopathic (solitary) T cell pseudolymphoma'</a>). In the 2018 update of the WHO-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas and in the 2016 revision of the WHO classification, the term "primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder" is, therefore, preferred [<a href="#rid1">1,4</a>].</p><p class="headingAnchor" id="H324713509"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder is increasingly recognized and is more common than the other rare subtypes of PTCL, accounting for 6 percent of all CTCL [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3348273444"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Most patients with primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder typically present with a solitary plaque or tumor, generally on the face, the neck, or the upper trunk  (<a class="graphic graphic_picture graphicRef103522" href="/z/d/graphic/103522.html" rel="external">picture 11</a>) [<a href="#rid45">45,46,48-51</a>]. Generalized skin lesions are a much less common presentation [<a href="#rid45">45,46</a>]. </p><p>Rare cases presenting with generalized skin lesions and large, rapidly growing tumors showing on histopathology more than 30 percent large pleomorphic T cells and/or a high proliferative fraction do not belong to this group [<a href="#rid48">48,49</a>]. Such cases usually have a more aggressive clinical behavior and should be classified as peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). (See  <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"</a>.)</p><p class="headingAnchor" id="H2139991237"><span class="h2">Pathologic features</span></p><p class="headingAnchor" id="H1494371565"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>On histopathologic examination, primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder is identical to idiopathic (solitary) T cell pseudolymphoma with a nodular growth pattern  (<a class="graphic graphic_picture graphicRef103537" href="/z/d/graphic/103537.html" rel="external">picture 12</a>) [<a href="#rid45">45-47</a>]. (See  <a class="medical medical_review" href="/z/d/html/15723.html" rel="external">"Cutaneous T cell pseudolymphomas", section on 'Idiopathic (solitary) T cell pseudolymphoma'</a>.)</p><p>These lesions show dense, nodular to diffuse infiltrates within the dermis, with a tendency to infiltrate the subcutis. There is a predominance of small-/medium-sized pleomorphic T cells; epidermotropism is generally mild or absent [<a href="#rid45">45,46,48-50</a>]. A small proportion (&lt;30 percent) of large pleomorphic cells may be present [<a href="#rid26">26</a>]. In almost all cases, there is a considerable admixture with small reactive CD8<sup>+</sup> T cells, B cells, plasma cells, and histiocytes, including multinucleated giant cells [<a href="#rid45">45,46,50</a>]. Eosinophils are generally few or absent.</p><p class="headingAnchor" id="H1865940484"><span class="h3">Immunophenotype</span><span class="headingEndMark"> — </span>By definition, primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder has a CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>-</sup>, CD30<sup>-</sup> phenotype, similar to idiopathic T cell pseudolymphoma (nodular/diffuse type). Loss of pan-T cell markers is uncommon, and cytotoxic proteins are not expressed [<a href="#rid45">45,46,48,50</a>]. Several studies showed that the medium-sized to large atypical CD4<sup>+</sup> T cells consistently express the follicular helper T cell markers PD-1, BCL6, and CXCL13 but (unlike angioimmunoblastic T cell lymphoma) not CD10  (<a class="graphic graphic_picture graphicRef103538" href="/z/d/graphic/103538.html" rel="external">picture 13</a>) [<a href="#rid46">46,50</a>]. The proliferation rate is low, varying between less than 5 percent and at most 20 percent. In some cases with plasma cells showing monotypic immunoglobulin light chain expression, differentiation from primary marginal zone lymphomas may be difficult [<a href="#rid52">52</a>]. Epstein-Barr virus is negative.</p><p class="headingAnchor" id="H1334410468"><span class="h3">Genetics</span><span class="headingEndMark"> — </span>Clonal T cell receptor gene rearrangements are detected in most cases [<a href="#rid46">46,50</a>]. Specific genetic abnormalities have not been described.</p><p class="headingAnchor" id="H2031985525"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder is based upon the clinical finding of a solitary plaque or nodule on the face or trunk that demonstrates the histopathologic and immunophenotypic features described above. An excisional biopsy can be performed for lesions that are small (&lt;2 cm) and well demarcated. For larger lesions, deep punch biopsies (≥4 mm) or incisional biopsies are appropriate for diagnosis. A careful clinicopathologic correlation is necessary for a correct diagnosis. </p><p class="headingAnchor" id="H4285820249"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder includes tumor stage MF and primary cutaneous PTCL, NOS. </p><p>Presentation with a solitary skin lesion; the presence of scattered, medium-sized to large CD4<sup>+</sup> T cells expressing PD-1; many admixed B cells, CD8<sup>+</sup> T cells, and histiocytes; and the low proliferation rate are useful criteria to differentiate this condition from MF and primary cutaneous PTCL, NOS [<a href="#rid46">46,53</a>]. (See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides", section on 'Morphology'</a> and  <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified", section on 'Pathology'</a>.) </p><p class="headingAnchor" id="H1409425915"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder lesions may resolve spontaneously after skin biopsy [<a href="#rid46">46,50</a>]. Persistent lesions can be treated with intralesional steroids, surgical excision, or, in rare instances, with radiotherapy [<a href="#rid45">45,46,48</a>].</p><p>Local recurrences after initial treatment are rarely observed. Patients have an excellent long-term prognosis and do not require further examinations or staging [<a href="#rid45">45,46,48</a>].</p><p class="headingAnchor" id="H3890661031"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122000.html" rel="external">"Society guideline links: Primary cutaneous lymphoma"</a>.)</p><p class="headingAnchor" id="H1566918739"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Primary cutaneous T cell lymphomas, rare subtypes, are a heterogeneous group of extremely rare T cell lymphomas that present primarily in the skin without evidence of extracutaneous involvement. A careful clinicopathologic correlation is the key to a correct diagnosis. (See <a class="local">'Introduction'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary cutaneous gamma-delta T cell lymphoma</strong> – Primary cutaneous gamma-delta T cell lymphoma (PCGD-TCL) is a rare lymphoma composed of a clonal proliferation of mature, activated gamma-delta T cells with a cytotoxic phenotype. It presents with disseminated plaques and/or ulceronecrotic nodules or tumors preferentially located on the extremities  (<a class="graphic graphic_picture graphicRef109196" href="/z/d/graphic/109196.html" rel="external">picture 1</a>). The neoplastic cells of PCGD-TCL characteristically have a T cell receptor-gamma/delta<sup>+</sup>, beta-F1<sup>-</sup>, CD3<sup>+</sup>, CD2<sup>+</sup>, CD5<sup>-</sup>, CD4<sup>-</sup>, CD8<sup>-</sup>, CD56<sup>+</sup> phenotype with strong expression of cytotoxic proteins  (<a class="graphic graphic_picture graphicRef109198" href="/z/d/graphic/109198.html" rel="external">picture 3</a>). PCGD-TCL has usually an aggressive clinical course, is resistant to multiagent chemotherapy, and has a poor prognosis. (See <a class="local">'Primary cutaneous gamma-delta T cell lymphoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary cutaneous CD8</strong><strong><sup>+</sup></strong><strong> aggressive epidermotropic cytotoxic T cell lymphoma</strong> – Primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T cell lymphoma (AECTCL) is a rare cutaneous lymphoma characterized by a proliferation of epidermotropic CD8<sup>+</sup> cytotoxic T cells, an aggressive clinical behavior, and poor prognosis. It typically presents with localized or disseminated eruptive papules, nodules, and tumors showing central ulceration and necrosis  (<a class="graphic graphic_picture graphicRef109201" href="/z/d/graphic/109201.html" rel="external">picture 5</a>). The neoplastic T cells show a beta-F1<sup>+</sup>, CD3<sup>+</sup>, CD8<sup>+</sup>, granzyme B<sup>+</sup>, perforin<sup>+</sup>, TIA-1<sup>+</sup>, CD45RA<sup>+/-</sup>, CD45RO<sup>-</sup>, CD2<sup>-/+</sup>, CD4<sup>-</sup>, CD5<sup>-</sup>, CD7<sup>+/-</sup> phenotype  (<a class="graphic graphic_picture graphicRef109207" href="/z/d/graphic/109207.html" rel="external">picture 7</a>). The clinical course is aggressive, and the response to chemotherapy is often disappointing. (See <a class="local">'Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T cell lymphoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary cutaneous acral CD8</strong><strong><sup>+</sup></strong><strong> T cell lymphoma</strong> – Primary cutaneous acral CD8<sup>+</sup> T cell lymphoma is a newly described entity histologically characterized by a diffuse infiltrate of medium-sized CD8<sup>+</sup> cytotoxic T cells suggesting a high-grade malignant lymphoma and an indolent clinical behavior. The tumor cells have a CD3<sup>+</sup>, CD4<sup>-</sup>, CD8<sup>+</sup>, TIA-1<sup>+</sup>, granzyme B<sup>-</sup>, CD30<sup>-</sup> T cell phenotype  (<a class="graphic graphic_picture graphicRef109235" href="/z/d/graphic/109235.html" rel="external">picture 9</a>). Surgical excision or radiotherapy usually result in complete remission. (See <a class="local">'Primary cutaneous acral CD8+ T cell lymphoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary cutaneous CD4</strong><strong><sup>+</sup></strong><strong> small/medium T cell lymphoproliferative disorder</strong> – Primary cutaneous CD4<sup>+</sup> small/medium T cell lymphoproliferative disorder is included as a provisional entity in the 2018 update of the World Health Organization (WHO)-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas and in the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissue. It includes or is a new term for:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary cutaneous CD4</strong><strong><sup>+</sup></strong><strong> small/medium T cell lymphoma</strong> – Presents with a solitary lesion (from the 2005 WHO-European Organization for Research and Treatment of Cancer and 2008 WHO classifications).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Idiopathic cutaneous T cell pseudolymphoma with a nodular growth pattern</strong> – Presents with a solitary plaque or tumor, generally on the face, the neck, or the upper trunk  (<a class="graphic graphic_picture graphicRef103522" href="/z/d/graphic/103522.html" rel="external">picture 11</a>). It is histologically characterized by a predominance of small to medium-sized CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>-</sup> T cells; the presence of scattered, large CD3<sup>+</sup>, CD4<sup>+</sup>, PD-1<sup>+</sup> T cells; and an abundant inflammatory infiltrate of small reactive CD8<sup>+</sup> T cells, B cells, and histiocytes.</p><p></p><p class="bulletIndent1">Lesions may resolve spontaneously. Persistent lesions can be treated with intralesional corticosteroids or surgical excision. (See <a class="local">'Primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133:1703.</a></li><li><a class="nounderline abstract_t">Tan SH, Sim CS, Ong BH. Cutaneous lymphomas other than mycosis fungoides in Singapore: a clinicopathological analysis using recent classification systems. Br J Dermatol 2003; 149:542.</a></li><li><a class="nounderline abstract_t">Park JH, Shin HT, Lee DY, et al. World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution. J Am Acad Dermatol 2012; 67:1200.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Goyal A, Goyal K, Bohjanen K, Pearson D. Epidemiology of primary cutaneous γδ T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma in the U.S.A. from 2006 to 2015: a Surveillance, Epidemiology, and End Results-18 analysis. Br J Dermatol 2019; 181:848.</a></li><li><a class="nounderline abstract_t">Guitart J, Weisenburger DD, Subtil A, et al. Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol 2012; 36:1656.</a></li><li><a class="nounderline abstract_t">Daniels J, Doukas PG, Escala MEM, et al. Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nat Commun 2020; 11:1806.</a></li><li><a class="nounderline abstract_t">Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111:838.</a></li><li><a class="nounderline abstract_t">Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101:3407.</a></li><li><a class="nounderline abstract_t">Merrill ED, Agbay R, Miranda RN, et al. Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas. Am J Surg Pathol 2017; 41:204.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Jaffe ES, Brousset P, et al. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol 2014; 38:e60.</a></li><li><a class="nounderline abstract_t">Garcia-Herrera A, Song JY, Chuang SS, et al. Nonhepatosplenic γδ T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol 2011; 35:1214.</a></li><li><a class="nounderline abstract_t">Kamijo H, Miyagaki T, Norimatsu Y, et al. Primary cutaneous γδ T-cell lymphoma with unusual immunophenotype: A case report and review of published work. J Dermatol 2020; 47:300.</a></li><li><a class="nounderline abstract_t">Rodríguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, et al. TCR-γ expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol 2013; 37:375.</a></li><li><a class="nounderline abstract_t">Pulitzer M, Geller S, Kumar E, et al. T-cell receptor-δ expression and γδ+ T-cell infiltrates in primary cutaneous γδ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. Histopathology 2018; 73:653.</a></li><li><a class="nounderline abstract_t">Barzilai A, Goldberg I, Shibi R, et al. Mycosis fungoides expressing gamma/delta T-cell receptors. J Am Acad Dermatol 1996; 34:301.</a></li><li><a class="nounderline abstract_t">Badje ED, Tejasvi T, Hristov A. γδ lymphomatoid papulosis type D: A histologic mimic of primary cutaneous γδ T-cell lymphoma. JAAD Case Rep 2019; 5:264.</a></li><li><a class="nounderline abstract_t">Magro CM, Wang X. Indolent primary cutaneous γ/δ T-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis. Am J Clin Pathol 2012; 138:50.</a></li><li><a class="nounderline abstract_t">Endly DC, Weenig RH, Peters MS, et al. Indolent course of cutaneous gamma-delta T-cell lymphoma. J Cutan Pathol 2013; 40:896.</a></li><li><a class="nounderline abstract_t">Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155:483.</a></li><li><a class="nounderline abstract_t">Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97:610.</a></li><li><a class="nounderline abstract_t">Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology 2015; 67:425.</a></li><li><a class="nounderline abstract_t">Guitart J, Martinez-Escala ME, Subtil A, et al. Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Mod Pathol 2017; 30:761.</a></li><li><a class="nounderline abstract_t">Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol 1990; 22:569.</a></li><li><a class="nounderline abstract_t">Quintanilla-Martinez L, Jansen PM, Kinney MC, et al. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol 2013; 139:491.</a></li><li><a class="nounderline abstract_t">Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102:2213.</a></li><li><a class="nounderline abstract_t">Bastidas Torres AN, Cats D, Out-Luiting JJ, et al. Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. Haematologica 2022; 107:702.</a></li><li><a class="nounderline abstract_t">Lee K, Evans MG, Yang L, et al. Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. Blood 2021; 138:2435.</a></li><li><a class="nounderline abstract_t">Willemze R. CD30-Negative Cutaneous T-Cell Lymphomas Other than Mycosis Fungoides. Surg Pathol Clin 2014; 7:229.</a></li><li><a class="nounderline abstract_t">Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 2010; 34:1168.</a></li><li><a class="nounderline abstract_t">Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95:3653.</a></li><li><a class="nounderline abstract_t">Massone C, Crisman G, Kerl H, Cerroni L. The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. Br J Dermatol 2008; 159:881.</a></li><li><a class="nounderline abstract_t">Haghighi B, Smoller BR, LeBoit PE, et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol 2000; 13:502.</a></li><li><a class="nounderline abstract_t">Mourtzinos N, Puri PK, Wang G, Liu ML. CD4/CD8 double negative pagetoid reticulosis: a case report and literature review. J Cutan Pathol 2010; 37:491.</a></li><li><a class="nounderline abstract_t">Plachouri KM, Weishaupt C, Metze D, et al. Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation. JAAD Case Rep 2017; 3:196.</a></li><li><a class="nounderline abstract_t">Cyrenne BM, Gibson JF, Subtil A, et al. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18:e85.</a></li><li><a class="nounderline abstract_t">Petrella T, Maubec E, Cornillet-Lefebvre P, et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol 2007; 31:1887.</a></li><li><a class="nounderline abstract_t">Swick BL, Baum CL, Venkat AP, Liu V. Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature. J Cutan Pathol 2011; 38:209.</a></li><li><a class="nounderline abstract_t">Li JY, Guitart J, Pulitzer MP, et al. Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face. Am J Dermatopathol 2014; 36:402.</a></li><li><a class="nounderline abstract_t">Greenblatt D, Ally M, Child F, et al. Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features. J Cutan Pathol 2013; 40:248.</a></li><li><a class="nounderline abstract_t">Kluk J, Kai A, Koch D, et al. Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient. J Cutan Pathol 2016; 43:125.</a></li><li><a class="nounderline abstract_t">Beltraminelli H, Müllegger R, Cerroni L. Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma? J Cutan Pathol 2010; 37:81.</a></li><li><a class="nounderline abstract_t">Wobser M, Roth S, Reinartz T, et al. CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas. Br J Dermatol 2015; 172:1573.</a></li><li><a class="nounderline abstract_t">Alberti-Violetti S, Fanoni D, Provasi M, et al. Primary cutaneous acral CD8 positive T-cell lymphoma with extra-cutaneous involvement: A long-standing case with an unexpected progression. J Cutan Pathol 2017; 44:964.</a></li><li><a class="nounderline abstract_t">Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol 2009; 31:317.</a></li><li><a class="nounderline abstract_t">Cetinözman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 2012; 36:109.</a></li><li><a class="nounderline abstract_t">Rijlaarsdam JU, Scheffer E, Meijer CJ, Willemze R. Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients. Cancer 1992; 69:717.</a></li><li><a class="nounderline abstract_t">Grogg KL, Jung S, Erickson LA, et al. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol 2008; 21:708.</a></li><li><a class="nounderline abstract_t">Garcia-Herrera A, Colomo L, Camós M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 2008; 26:3364.</a></li><li><a class="nounderline abstract_t">Rodríguez Pinilla SM, Roncador G, Rodríguez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol 2009; 33:81.</a></li><li><a class="nounderline abstract_t">James E, Sokhn JG, Gibson JF, et al. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leuk Lymphoma 2015; 56:951.</a></li><li><a class="nounderline abstract_t">Bakr F, Wain EM, Barlow R, Robson A. Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder or Primary Cutaneous Marginal Zone B-Cell Lymphoma? Two Distinct Entities With Overlapping Histopathological Features. Am J Dermatopathol 2021; 43:e204.</a></li><li><a class="nounderline abstract_t">Bakels V, van Oostveen JW, van der Putte SC, et al. Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas. Am J Pathol 1997; 150:1941.</a></li></ol></div><div id="topicVersionRevision">Topic 103306 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635287" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510987" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cutaneous lymphomas other than mycosis fungoides in Singapore: a clinicopathological analysis using recent classification systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22521781" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30951189" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiology of primary cutaneousγδT-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma in the U.S.A. from 2006 to 2015: a Surveillance, Epidemiology, and End Results-18 analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23073324" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : CutaneousγδT-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32286303" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934071" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522013" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27879514" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary CutaneousγδT-Cell Lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25025449" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21753698" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : NonhepatosplenicγδT-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912565" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Primary cutaneousγδT-cell lymphoma with unusual immunophenotype: A case report and review of published work.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348211" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : TCR-γexpression in primary cutaneous T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29893430" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : T-cell receptor-δexpression andγδ+ T-cell infiltrates in primary cutaneousγδT-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8642099" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mycosis fungoides expressing gamma/delta T-cell receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30891476" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : γδlymphomatoid papulosis type D: A histologic mimic of primary cutaneousγδT-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22706857" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Indolent primary cutaneousγ/δT-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23379625" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Indolent course of cutaneous gamma-delta T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433941" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548603" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24438036" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28128277" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2138636" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23525618" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12750155" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33792220" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34432866" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26837200" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : CD30-Negative Cutaneous T-Cell Lymphomas Other than Mycosis Fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20661014" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845893" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18644018" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10824921" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19614989" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : CD4/CD8 double negative pagetoid reticulosis: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28443307" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29223388" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18043044" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083681" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394306" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23189944" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26423705" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19602068" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25524664" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28796362" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Primary cutaneous acral CD8 positive T-cell lymphoma with extra-cutaneous involvement: A long-standing case with an unexpected progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461234" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989349" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1730122" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18311111" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541895" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987541" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24996443" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34231494" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder or Primary Cutaneous Marginal Zone B-Cell Lymphoma? Two Distinct Entities With Overlapping Histopathological Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176388" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
